| Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer JP Robichaux, YY Elamin, Z Tan, BW Carter, S Zhang, S Liu, S Li, T Chen, ... Nature medicine 24 (5), 638-646, 2018 | 436 | 2018 |
| Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth B Hu, Q Wang, YA Wang, S Hua, CEG Sauvé, D Ong, ZD Lan, Q Chang, ... Cell 167 (5), 1281-1295. e18, 2016 | 242 | 2016 |
| Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer W Yao, JL Rose, W Wang, S Seth, H Jiang, A Taguchi, J Liu, L Yan, ... Nature 568 (7752), 410-414, 2019 | 151 | 2019 |
| Candidate antimetastasis drugs suppress the metastatic capacity of breast cancer cells by reducing membrane fluidity W Zhao, S Prijic, BC Urban, MJ Tisza, Y Zuo, L Li, Z Tan, X Chen, SA Mani, ... Cancer research 76 (7), 2037-2049, 2016 | 142 | 2016 |
| Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment P Chen, WH Hsu, A Chang, Z Tan, Z Lan, A Zhou, DJ Spring, FF Lang, ... Cancer discovery 10 (3), 371-381, 2020 | 117 | 2020 |
| Computational polypharmacology: a new paradigm for drug discovery R Chaudhari, Z Tan, B Huang, S Zhang Expert opinion on drug discovery 12 (3), 279-291, 2017 | 101 | 2017 |
| An up-to-date overview of computational polypharmacology in modern drug discovery R Chaudhari, LW Fong, Z Tan, B Huang, S Zhang Expert opinion on drug discovery 15 (9), 1025-1044, 2020 | 52 | 2020 |
| DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors S Chamakuri, S Lu, MN Ucisik, KM Bohren, YC Chen, HC Du, JC Faver, ... Proceedings of the National Academy of Sciences 118 (36), e2111172118, 2021 | 46 | 2021 |
| A noncoding RNA modulator potentiates phenylalanine metabolism in mice Y Li, Z Tan, Y Zhang, Z Zhang, Q Hu, K Liang, Y Jun, Y Ye, YC Li, C Li, ... Science 373 (6555), 662-673, 2021 | 43 | 2021 |
| Polypharmacology in drug development: a minireview of current technologies Z Tan, R Chaudhai, S Zhang ChemMedChem 11 (12), 1211-1218, 2016 | 41 | 2016 |
| Methylation of HSP70 orchestrates its binding to and stabilization of BCL2 mRNA and renders pancreatic cancer cells resistant to therapeutics L Wang, Z Jia, D Xie, T Zhao, Z Tan, S Zhang, F Kong, D Wei, K Xie Cancer Research 80 (20), 4500-4513, 2020 | 34 | 2020 |
| Comprehensive modeling and discovery of mebendazole as a novel TRAF2-and NCK-interacting kinase inhibitor Z Tan, L Chen, S Zhang Scientific reports 6 (1), 33534, 2016 | 33 | 2016 |
| FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia V Seda, E Vojackova, L Ondrisova, L Kostalova, S Sharma, T Loja, ... Blood, The Journal of the American Society of Hematology 138 (9), 758-772, 2021 | 27 | 2021 |
| Curation and analysis of multitargeting agents for polypharmacological modeling AS Reddy, Z Tan, S Zhang Journal of chemical information and modeling 54 (9), 2536-2543, 2014 | 22 | 2014 |
| Past, present, and future of targeting ras for cancer therapies Z Tan, S Zhang Mini reviews in medicinal chemistry 16 (5), 345-357, 2016 | 21 | 2016 |
| Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections RK Modukuri, Z Yu, Z Tan, HM Ta, MN Ucisik, Z Jin, JL Anglin, KL Sharma, ... Proceedings of the National Academy of Sciences 119 (22), e2122506119, 2022 | 18 | 2022 |
| Discovery of highly potent and BMPR2-selective kinase inhibitors using DNA-encoded chemical library screening RK Modukuri, D Monsivais, F Li, M Palaniappan, KM Bohren, Z Tan, ... Journal of Medicinal Chemistry 66 (3), 2143-2160, 2023 | 13 | 2023 |
| Tumor-associated nonmyelinating Schwann cell–expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion C Sun, Y Ye, Z Tan, Y Liu, Y Li, W Hu, K Liang, SD Egranov, LA Huang, ... Science Advances 9 (5), eadd6995, 2023 | 12 | 2023 |
| Interaction between nanoparticles and charged phospholipid membranes B Huang, Z Tan, K Bohinc, S Zhang Physical Chemistry Chemical Physics 20 (46), 29249-29263, 2018 | 10 | 2018 |
| OA 12.01 the preclinical and clinical activity of poziotinib, a potent, selective inhibitor of EGFR Exon 20 mutant NSCLC Y Elamin, J Robichaux, V Lam, A Tsao, C Lu, G Blumenschein, J Kurie, ... Journal of Thoracic Oncology 12 (11), S1776, 2017 | 9 | 2017 |
Rajan ChaudhariM D Anderson Cancer CenterVerified email at mdanderson.org
